Akari Therapeutics is progressing its proprietary antibody-drug conjugates featuring the novel PH1 payload targeting RNA splicing in cancer cells. The company has advanced IND enabling studies for AKTX-101 with plans to initiate a Phase 1 clinical trial by late 2026 or early 2027. Strategic partnerships for GMP manufacturing and a growing patent portfolio support its biopharmaceutical platform. However, Akari faces typical early-stage biotech challenges including limited liquidity and ongoing operating losses, making successful capital raising critical for future operations.